Clinical Trial Update: Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on trametinib for recurrent or progressive low-grade ovarian cancer and peritoneal serous cancers (Phase 2/Phase 3) with results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade Serous Ovarian Carcinoma
• Ovarian Micropapillary Serous Carcinoma
• Ovarian Serous Borderline Tumor
• Ovarian Serous Carcinoma
• Peritoneal Serous Carcinoma

Drugs mentioned

• Trametinib (trametinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2020-09-29